These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 34821021)

  • 1. A multi-site, nurse-coordinated hepatitis C model of care in primary care and community services in Melbourne, Australia.
    Harney BL; Whitton B; Paige E; Brereton R; Weiss R; Membrey D; Wade AJ; Iser D; Kemp W; Roberts SK; Spelman T; Sacks-Davis R; Hellard ME; Doyle JS
    Liver Int; 2022 Mar; 42(3):522-531. PubMed ID: 34821021
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitative evaluation of an integrated nurse model of care providing hepatitis C treatment to people attending homeless services in Melbourne, Australia.
    Harney BL; Whitton B; Lim C; Paige E; McDonald B; Nolan S; Pemberton D; Hellard ME; Doyle JS
    Int J Drug Policy; 2019 Oct; 72():195-198. PubMed ID: 30981613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatitis C treatment in a co-located mental health and alcohol and drug service using a nurse-led model of care.
    Harney BL; Brereton R; Whitton B; Pietrzak D; Paige E; Roberts SK; Birks S; Saraf S; Hellard ME; Doyle JS
    J Viral Hepat; 2021 May; 28(5):771-778. PubMed ID: 33599036
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatitis C virus testing, liver disease assessment and treatment uptake among people who inject drugs pre- and post-universal access to direct-acting antiviral treatment in Australia: The LiveRLife study.
    Bajis S; Grebely J; Hajarizadeh B; Applegate T; Marshall AD; Ellen Harrod M; Byrne J; Bath N; Read P; Edwards M; Gorton C; Hayllar J; Cock V; Peterson S; Thomson C; Weltman M; Jefferies M; Wood W; Haber P; Ezard N; Martinello M; Maher L; Dore GJ;
    J Viral Hepat; 2020 Mar; 27(3):281-293. PubMed ID: 31698545
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eliminating hepatitis C in Australia: a novel model of hepatitis C testing and treatment for people who inject drugs at a medically supervised injecting facility.
    MacIsaac MB; Whitton B; Hubble A; Cogger S; Penn M; Weeks A; Elmore K; Pemberton D; Anderson J; Howard R; McKeever U; Papaluca T; Hellard ME; Stoove M; Wilson D; Pedrana A; Doyle J; Clark N; Holmes J; Thompson AJ
    Med J Aust; 2023 Apr; 218(6):256-261. PubMed ID: 36919230
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors Associated with Sustained Virologic Response to Hepatitis C Treatment in a Homeless-Experienced Cohort in Boston, 2014-2020.
    Beiser ME; Shaw LC; Wilson GA; Muse KO; Shores SK; Baggett TP
    J Gen Intern Med; 2023 Mar; 38(4):865-872. PubMed ID: 36127534
    [TBL] [Abstract][Full Text] [Related]  

  • 7. On-site testing and case management to improve hepatitis C care in drug users: a prospective, longitudinal, multicenter study in the DAA era.
    Busschots D; Bielen R; Koc ÖM; Heyens L; Dercon E; Verrando R; Janssens F; Van den Bergh L; Van Lint P; Bruckers L; Nevens F; Robaeys G
    BMC Public Health; 2021 Aug; 21(1):1574. PubMed ID: 34416867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Results of a Model of Delivering Hepatitis C Care in a Homeless Metropolitan Population in England.
    Guerra-Veloz MF; Han K; Oakes K; Robertson D; Mohamed A; Cannon M; Barnabas A; Shah S; Halford R; Dusheiko G; Agarwal K
    Am J Gastroenterol; 2023 Jun; 118(6):991-1000. PubMed ID: 36191276
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Delivering direct acting antiviral therapy for hepatitis C to highly marginalised and current drug injecting populations in a targeted primary health care setting.
    Read P; Lothian R; Chronister K; Gilliver R; Kearley J; Dore GJ; van Beek I
    Int J Drug Policy; 2017 Sep; 47():209-215. PubMed ID: 28587943
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of direct-acting antiviral therapy among Aboriginal and Torres Strait Islander peoples with HCV infection in Australia: A national real-world cohort (REACH-C).
    Hudson-Buhagiar J; Carson J; Monaghan S; Collie P; Nelson R; Van Gessel H; Read P; Hanson J; Monaghan R; Matthews G; Dore GJ; Martinello M;
    J Viral Hepat; 2023 May; 30(5):386-396. PubMed ID: 36651627
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single-visit hepatitis C point-of-care testing, linkage to nursing care, and peer-supported treatment among people with recent injecting drug use at a peer-led needle and syringe program: The TEMPO Pilot Study.
    Grebely J; Gilliver R; McNaughton T; Conway A; Cunningham E; Henderson C; Hadlow B; Molloy K; Doab A; Tillakeratne S; Pepolim L; Harrod ME; Dore GJ; Read P
    Int J Drug Policy; 2023 Apr; 114():103982. PubMed ID: 36863287
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of response-guided directly observed pegylated interferon and self-administered ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE study.
    Grebely J; Dalgard O; Cunningham EB; Hajarizadeh B; Foster GR; Bruggmann P; Conway B; Backmund M; Robaeys G; Swan T; Amin J; Marks PS; Quiene S; Applegate TL; Weltman M; Shaw D; Dunlop A; Hellard M; Bruneau J; Midgard H; Bourgeois S; Staehelin C; Dore GJ;
    Int J Drug Policy; 2017 Sep; 47():177-186. PubMed ID: 28624134
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world hepatitis C prevalence and treatment uptake at opioid agonist therapy clinics in Ontario, Canada.
    Wolfson-Stofko B; Hirode G; Vanderhoff A; Karkada J; Capraru C; Biondi MJ; Hansen B; Shah H; Janssen HLA; Feld JJ
    J Viral Hepat; 2024 May; 31(5):240-247. PubMed ID: 38385850
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatitis C virus testing, liver disease assessment and direct-acting antiviral treatment uptake and outcomes in a service for people who are homeless in Sydney, Australia: The LiveRLife homelessness study.
    Bajis S; Grebely J; Cooper L; Smith J; Owen G; Chudleigh A; Hajarizadeh B; Martinello M; Adey S; Read P; Gilliver R; Applegate T; Treloar C; Maher L; Dore GJ
    J Viral Hepat; 2019 Aug; 26(8):969-979. PubMed ID: 30980785
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treating people where they are: Nurse-led micro-elimination of hepatitis C in supported housing sites for networks of people who inject drugs in Victoria, Canada.
    Selfridge M; Barnett T; Lundgren K; Guarasci K; Milne R; Drost A; Fraser C
    Public Health Nurs; 2022 Sep; 39(5):1009-1016. PubMed ID: 35537120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High Effectiveness of Broad Access Direct-Acting Antiviral Therapy for Hepatitis C in an Australian Real-World Cohort: The REACH-C Study.
    Yee J; Carson JM; Hajarizadeh B; Hanson J; O'Beirne J; Iser D; Read P; Balcomb A; Doyle JS; Davies J; Martinello M; Marks P; Dore GJ; Matthews GV;
    Hepatol Commun; 2022 Mar; 6(3):496-512. PubMed ID: 34729957
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatitis C Virus Reinfection in a Real-World Cohort of Homeless-Experienced Individuals in Boston.
    Beiser ME; Shaw LC; Shores SK; Carson JM; Hajarizadeh B
    Clin Infect Dis; 2023 Jul; 77(1):46-55. PubMed ID: 36869823
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of point-of-care hepatitis C testing in needle and syringe exchange programs on linkage to care and treatment uptake among people who inject drugs: An Australian pilot study.
    Howell J; Traeger MW; Williams B; Layton C; Doyle JS; Latham N; Draper B; Bramwell F; Membrey D; McPherson M; Roney J; Stoové M; Thompson AJ; Hellard ME; Pedrana A
    J Viral Hepat; 2022 May; 29(5):375-384. PubMed ID: 35274403
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of a person-centred, nurse-led model of care delivering hepatitis C testing and treatment in priority settings: a mixed-methods evaluation of the Tasmanian Eliminate Hepatitis C Australia Outreach Project, 2020-2022.
    Dawe J; Hughes M; Christensen S; Walsh L; Richmond JA; Pedrana A; Wilkinson AL; Owen L; Doyle JS;
    BMC Public Health; 2023 Nov; 23(1):2289. PubMed ID: 37985979
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatitis C antibody testing among opioid agonist therapy recipients, Victoria, Australia, 2012 to 2020.
    Dawe J; Wilkinson AL; Asselin J; Carter A; Pedrana A; Traeger MW; Thomas AJ; Curtis M; Cooper M; Howell J; Doyle JS; Hellard ME; Stoové M;
    Int J Drug Policy; 2022 Jun; 104():103696. PubMed ID: 35490624
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.